Back to Search Start Over

Chinese moyamoya disease study:cohort profile

Authors :
Fang-Bin Hao
Cong Han
Gan Gao
Si-meng Liu
Min-jie Wang
Ri-Miao Yang
Zheng-Xing Zou
Dan Yu
Caihong Sun
Qian Zhang
Houdi Zhang
Qing-Bao Guo
Xiao-Peng Wang
Xuxuan Shen
Heguan Fu
JingJie Li
Zheng-shan Zhang
Xiang-Yang Bao
Jie Feng
Bin Li
Bin Ren
Hui Wang
Qian-Nan Wang
Songtao Pei
Bo Zhao
Zhenglong Zou
Yi-Qin Han
Huaiyu Tong
Zhenghui Sun
Miao Liu
Lian Duan
Publication Year :
2023
Publisher :
Cold Spring Harbor Laboratory, 2023.

Abstract

BackgroundThe etiology and natural course of moyamoya disease (MMD) remain unknown. This study evaluated the natural course and etiology of MMD using data from the Chinese MMD (C-MMD) cohort study.MethodsThe C-MMD cohort consisted of 6,167 patients with MMD treated at our center over the past 20 years. We analyzed the medical history and laboratory and imaging examination results of the patients at different stages of the disease to identify common features of MMD.ResultsThe median age for symptom onset was 32 years. The age distribution was bimodal; the highest peak was between ages 35 and 45 years, with a smaller peak between ages 3 and 9 years. The female-to-male ratio was 1:1. The disease occurred mainly in the Han people and was rarely observed in minority nationalities. In our cohort, a transient ischemic attack was the most common initial clinical manifestation (46.3%); others included infarction (25.0%), hemorrhage (15.1%), and headache (7.9%).ConclusionsThe C-MMD cohort is currently one of the largest single-center MMD cohorts in the world. This study provides baseline data for future research on the etiology and natural course of MMD.Clinical Trial RegistrationThis study has been registered in the Chinese Clinical trial registry (registration number: ChiCTR2200064160).

Details

Database :
OpenAIRE
Accession number :
edsair.doi...........2d66eb794937b84ba6d954b9abb118c5
Full Text :
https://doi.org/10.1101/2023.03.20.23287508